On April 12, 2000, photodynamic therapy (PDT) with verteporfin (Visudyne®) is approved by the FDA for the treatment of neovascular AMD. Developed in the 1990s by Joan W. Miller, MD and Evangelos S. Gragoudas, MD, Visudyne® is the first pharmacologic treatment for retinal disease.

From the EyeSmart program of the American Academy of Ophthalmology

Select Citations:


Lucentis®, a fragment of the anti-VEGF antibody bevacizumab, enters clinical testing for AMD.



Joan W. Miller, MD, FARVOJoan W. Miller, MD, is named Chair of the HMS Department of Ophthalmology and Chief of Ophthalmology at Mass. Eye and Ear. She is the first woman to hold this dual role.


See also: Date